$ACT News Pfizer sales fall less than expected 7:34

New Post Public Reply Private Reply Replies (0) Message Board

Oct 28, 2014 at 11:15 AM

$ACT News

Pfizer sales fall less than expected 7:34 a.m. Today - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:49 p.m. Oct. 7, 2014 - Russ Britt
Actavis agrees to acquire Durata Therapeutics 8:44 a.m. Oct. 6, 2014 - Tess Stynes
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:41 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:27 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:03 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang

3 Generics Stocks to Buy Now - Analyst Blog 47 min ago - Zacks.com
Pfizer Sales Drop Less Than Expected 7:36 a.m. Today - The Wall Street Journal Interactive Edition
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog 5:40 p.m. Oct. 27, 2014 - Zacks.com
Lannett Co. Gets Growth Rx In Generic Drugs Group 4:59 p.m. Oct. 27, 2014 - Investors Business Daily
Will Growth Measures Reflect on Aetna (AET) Q3 Earnings? - Analyst Blog 2:21 p.m. Oct. 27, 2014 - Zacks.com
3 Drugs Stocks Dragging The Industry Down 1:20 p.m. Oct. 27, 2014 - TheStreet.com
The Medicines Co.'s Q3 Earnings Fall Y/Y, Guidance Lowered - Analyst Blog 1:00 p.m. Oct. 27, 2014 - Zacks.com
Allergan Lifts Guidance; Valeant Suggests Higher Bid 11:17 a.m. Oct. 27, 2014 - Investors Business Daily
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog 4:11 p.m. Oct. 24, 2014 - Zacks.com
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog 3:48 p.m. Oct. 24, 2014 - Zacks.com
Stock Charts Show Stocks' Health, Optimal Buy Point 4:54 p.m. Oct. 23, 2014 - Investors Business Daily
Illumina Breaks Out Of Double-Bottom Base 4:53 p.m. Oct. 22, 2014 - Investors Business Daily
3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion 9:13 a.m. Oct. 22, 2014 - 247WallSt.com
Akorn (AKRX) Looks Good: Stock Adds 5.8% in Session - Tale of the Tape 9:04 a.m. Oct. 22, 2014 - Zacks.com
Synergy Pharma presents plecanatide IBS-C clinical trial results 10:11 a.m. Oct. 21, 2014 - Seeking Alpha
Digging Deeper Into Valeant's Organic Growth Claims 7:14 a.m. Oct. 21, 2014 - Seeking Alpha
PEG Ratio vs. the P/E Ratio - Screen of the Week 4:14 a.m. Oct. 21, 2014 - Zacks.com
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
Akorn Finds Institutional Support In Base 5:36 p.m. Oct. 17, 2014 - Investors Business Daily
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog 4:40 p.m. Oct. 17, 2014 - Zacks.com

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actavis to Acquire Durata Therapeutics, Inc. 8:00 a.m. Oct. 6, 2014 - PR Newswire - PRF
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 10:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 9:39 a.m. Sept. 24, 2014 - PR Newswire - PRF
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension 5:10 p.m. Sept. 9, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...